ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

IPA ImmunoPrecise Antibodies Ltd

0.5667
-0.0333 (-5.55%)
Pre Market
Last Updated: 13:32:08
Delayed by 15 minutes
Share Name Share Symbol Market Type
ImmunoPrecise Antibodies Ltd NASDAQ:IPA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.0333 -5.55% 0.5667 0.5521 0.5667 347,016 13:32:08

IPA to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference

04/12/2024 1:00pm

Business Wire


ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart


From Nov 2024 to Jan 2025

Click Here for more ImmunoPrecise Antibodies Charts.

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced it will be presenting at The Benchmark Company’s 13th Annual Discovery One-on-One Investor Conference to be held Wednesday, December 11th, 2024, at the New York Athletic Club in New York City.

The conference offers emerging growth, and dynamic publicly traded companies access to institutional and individual investors in a unique one-on-one format. During the event, Dr. Jennifer Bath, President and CEO, will be participating in one-on-one meetings with investors and analysts throughout the day. To schedule a one-on-one meeting with Dr. Jennifer Bath, please first register here for the conference. Once you are registered, you'll gain access to the platform to submit your meeting request.

About The Benchmark Company

The Benchmark Company is an institutionally focused, research driven, sales trading and investment banking firm. We were founded in 1988 and are headquartered in New York City. Our focus is on fostering the long-term success of our corporate clients through raising capital, providing strategic advisory services, generating insightful research, and developing institutional sponsorship by leveraging the firm’s sales, trading, and equity research capabilities. https://www.benchmarkcompany.com.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and is known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family”).

Investor Relations Contact investors@ipatherapeutics.com

1 Year ImmunoPrecise Antibodies Chart

1 Year ImmunoPrecise Antibodies Chart

1 Month ImmunoPrecise Antibodies Chart

1 Month ImmunoPrecise Antibodies Chart

Your Recent History

Delayed Upgrade Clock